Van Eck Associates Corp
- SEC CIK
- 0000869178
- Latest filing
- Aug 14, 2026
RARE holding history
Ultragenyx Pharmaceutical Inc. in every 13F filed by Van Eck Associates Corp, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RARE overviewAll 13F holders of RAREFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 12
- Since Q2 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −4,357−100.0% | Sold out | Holders |
| Q1 2026 | 4,357 | $91.0K | <0.1% | −810−15.7% | Reduced | Holders |
| Q4 2025 | 5,167 | $119.0K | <0.1% | +2,517+95.0% | Added | Holders |
| Q3 2025 | 2,650 | $80.0K | <0.1% | +549+26.1% | Added | Holders |
| Q2 2025 | 2,101 | $76.0K | <0.1% | +308+17.2% | Added | Holders |
| Q1 2025 | 1,793 | $65.0K | <0.1% | +33+1.9% | Added | Holders |
| Q4 2024 | 1,760 | $74.0K | <0.1% | +273+18.4% | Added | Holders |
| Q3 2024 | 1,487 | $81.0K | <0.1% | −457−23.5% | Reduced | Holders |
| Q2 2024 | 1,944 | $80.0K | <0.1% | +36+1.9% | Added | Holders |
| Q1 2024 | 1,908 | $89.0K | <0.1% | +330+20.9% | Added | Holders |
| Q4 2023 | 1,578 | $75.0K | <0.1% | +400+34.0% | Added | Holders |
| Q3 2023 | 1,178 | $42.0K | <0.1% | +29+2.5% | Added | Holders |
| Q2 2023 | 1,149 | $53.0K | <0.1% | +1,149 | New | Holders |